Technical Review: Peripheral mRNA-LNP Vaccination Generates Protective Brain-Resident Memory T Cells Against Intracranial Tumors

Authors: Matthew R. Mix, Collin M. Stofer, Madison H. Harken, Victor P. Batista, et al.

Affiliations: University of Iowa, Mayo Clinic

Journal: Journal of Clinical Investigation | DOI: 10.1172/JCI197812 | Published April 15, 2026

Background: The Challenge of Brain Tumor Immunotherapy

Brain tumors remain among the most lethal forms of cancer, with limited treatment options and poor prognosis. Despite advances in immunotherapy, durable responses in brain tumors remain elusive. A major barrier is the inability to establish persistent, functional immune surveillance within the brain parenchyma itself.

Tissue-resident memory (TRM) CD8+ T cells are non-circulating lymphocytes that persist at barrier tissues and provide rapid local immune defense. These cells have been well-characterized in skin, lung, and gut. However, whether TRM can be generated in the brain via peripheral vaccination and protect against intracranial malignancy was previously unknown.

mRNA-LNP vaccines have emerged as a transformative immunization platform following the COVID-19 pandemic. This study by Mix et al. directly tested whether peripheral mRNA-LNP vaccination could generate tumor-specific brain TRM capable of protecting against intracranial tumors.

Tumor-Specific Brain TRM Provide Durable Protection

Using OT-I TCR-transgenic CD8+ T cells combined with a dendritic cell prime / recombinant Listeria monocytogenes boost (DC-rLM) immunization strategy, the researchers demonstrated that tumor-specific T cells seeded the brain and acquired canonical TRM markers including CD69, CD49a, and CXCR6.

Critically, when circulating memory T cells were depleted via anti-Thy1.1 antibody treatment, leaving only brain-resident T cells, mice were still protected against intracranial B16-OVA melanoma challenge. Tumor-specific OT-I TRM conferred significantly improved survival, demonstrating that brain-resident T cells alone are sufficient for intracranial tumor protection.

The authors further demonstrated that brain TRM persist in surviving mice for over 100 days after initial tumor challenge. These long-lived TRM retained their functional capacity, as tumor-surviving mice were completely protected upon intracranial rechallenge even when circulating T cells were depleted. Brain TRM also protected against a second antigen-matched challenge using LCMV delivered intracranially.

Brain TRM Restrain Peripheral Immunosuppression

A surprising finding was that brain TRM modulated systemic immune responses to tumor challenge. While naive mice challenged with intracranial B16-OVA exhibited profound peripheral immunosuppression with decreased splenic weight, reduced thymic cellularity, and infiltration of myeloid cells into the brain, mice harboring tumor-specific brain TRM were largely spared these pathological changes. Furthermore, OT-I brain TRM did not upregulate PD-1, suggesting that TRM-based protection operates through a sustained immune equilibrium rather than a conventional inflammatory response.

Peripheral mRNA-LNP Vaccination Generates Brain TRM

To translate these findings toward a clinically viable platform, the authors developed an mRNA-LNP vaccine encoding multiple melanoma-associated CD8+ T cell epitopes. The construct, termed UbMel-OVA, encoded a string of H2-Db and H2-Kb restricted epitopes including TRP1, TRP2, GP100, and OVA, flanked by proteasomal cleavage sequences for optimal antigen processing.

The mRNA was packaged into lipid nanoparticles (LNPs) using the PreciGenome NanoGenerator Flex microfluidic mixing system with a CHP-MIX-4 micromixer chip. The formulation used PreciGenome's LipidFlex neutral lipid mixture (#PG-SYN_LF1ML) with cationic lipid SM-102, at an N/P ratio of 6:4, with a 3:1 aqueous-to-organic flow rate ratio at a total flow rate of 3 mL/min. LNP size was measured at 90-125 nm by dynamic light scattering.

Mice prime-boosted with UbMel-OVA mRNA-LNP vaccine via intramuscular or intravenous administration generated OT-I T cells that seeded the brain and acquired canonical TRM signatures. Remarkably, peripheral mRNA-LNP vaccination generated brain TRM that distributed widely throughout the brain, including near gray matter-white matter junction regions where metastasis-susceptible niches form.

mRNA-LNP Vaccine-Induced Brain TRM Durably Protect Against Intracranial Tumors

Mice prime-boosted with UbMel-OVA or UbFlu-GP33 mRNA-LNP vaccines were treated with antibodies to deplete circulating T cells, and then challenged intracranially with B16-OVA melanoma or GL261-QUAD-Luc glioblastoma cells. The results were striking: mRNA-LNP vaccination-induced brain TRM durably protected mice against both tumor types. In the GL261 glioblastoma model, vaccination substantially lowered tumor burden based on quantitative bioluminescence imaging. Tumor-specific brain TRM robustly proliferated and upregulated granzyme B expression, confirming active cytotoxic function.

The researchers further demonstrated that therapeutic mRNA-LNP vaccination, administered after tumor establishment using a subcutaneous B16-OVA model, outperformed anti-PD-L1 checkpoint blockade in controlling tumor growth and improving survival. Vaccine-induced CD8+ T cells were detected across multiple tissues with TRM-like phenotypes.

Significance and Outlook

This study provides the first comprehensive evidence that peripheral mRNA-LNP vaccination can generate tumor-specific brain TRM that durably protect against intracranial malignancy. The work demonstrates that TRM-based immune surveillance in the brain is achievable through a clinically translatable vaccination platform, that brain TRM restrain tumor-associated immunosuppression, and that both prophylactic and therapeutic mRNA-LNP vaccination showed efficacy.

PreciGenome Products Featured:

NanoGenerator Flex - Microfluidic LNP Formulation System with CHP-MIX-4 micromixer chip, used for all mRNA-LNP vaccine preparations in this study.

LipidFlex Neutral Lipid Mixture (#PG-SYN_LF1ML) - Pre-formulated lipid mixture with SM-102 used at N/P 6:4 to produce 90-125 nm LNPs for mRNA vaccine delivery.

Full Paper: https://doi.org/10.1172/JCI197812